UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

PloS one, 2022-01, Vol.17 (6), p.e0269399-e0269399

2022

Volltextzugriff (PDF)

Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

Annals of oncology, 2019-10, Vol.30, p.v834

2019

Volltextzugriff (PDF)

CN64 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

Annals of oncology, 2019-10, Vol.30, p.v834-v834

2019

Volltextzugriff (PDF)

CN64Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1013PIncidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Annals of oncology, 2019-10, Vol.30, p.v414

2019

Volltextzugriff (PDF)

1013P - Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Annals of oncology, 2019-10, Vol.30, p.v414-v414

2019

Volltextzugriff (PDF)

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

PloS one, 2022-01, Vol.17 (6)

2022

Volltextzugriff (PDF)

Efficacy and safety of FOLFIRI/aflibercept after failure of an oxaliplatin-based regimen

PloS one, 2022-06, Vol.17 (6), p.e0269399

2022

Volltextzugriff (PDF)

Efficacy and safety of FOLFIRI/aflibercept

PloS one, 2022-06, Vol.17 (6), p.e0269399

2022

Volltextzugriff (PDF)

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

Scientific reports, 2022-08, Vol.12 (1), p.14612-14612, Article 14612

2022

Volltextzugriff (PDF)

Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain

BMJ open quality, 2024-06, Vol.13 (2), p.e002732

2024

Volltextzugriff (PDF)

Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241272957

2024

Volltextzugriff (PDF)

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study

Translational lung cancer research, 2023-08, Vol.12 (8), p.1812-1815

2023

Volltextzugriff (PDF)

96 Real-World Evidence About Efficacy and Post-progression Outcomes of Second Line Osimertinib in EGFRm NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107657, Article 107657

2024

Volltextzugriff (PDF)

Recent advances and future strategies in first-line treatment of ES-SCLC

European journal of cancer (1990), 2024-03, Vol.200, p.113581-113581, Article 113581

2024

Volltextzugriff (PDF)

25P Differential response to platinum agents of patients carrying the germline BRCA1 c.211 A>G pathogenic variant

Annals of oncology, 2022-10, Vol.33, p.S1391-S1391

2022

Volltextzugriff (PDF)

32P Validation of the Scottish Immunotherapy Prognostic Score (SIPS) in NSCLC patients treated with first-line pembrolizumab

ESMO open, 2024-02, Vol.9, p.102360, Article 102360

2024

Volltextzugriff (PDF)

P42.03 Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1081-S1081

2021

Volltextzugriff (PDF)

P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors

Annals of oncology, 2021-07, Vol.32, p.S159-S160

2021

Volltextzugriff (PDF)

P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies

Annals of oncology, 2021-07, Vol.32, p.S106-S107

2021

Volltextzugriff (PDF)

131P Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S768-S769

2021

Volltextzugriff (PDF)

204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107765, Article 107765

2024

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(32)
Journals@Ovid
(18)
IngentaConnect
(11)
ScienceDirect
(6)
Publisher or Other Site
(6)
IngentaConnect Journals
(5)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(4)
MEDLINE
(4)
Wiley Online Library All Journals
(2)
BMJ Journals
(1)
Nature
(1)
SAGE Journals
(1)

7 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

CN64 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

CN64Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center

1013PIncidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

1013P - Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept after failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain

Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study

Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma

The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

96 Real-World Evidence About Efficacy and Post-progression Outcomes of Second Line Osimertinib in EGFRm NSCLC

Recent advances and future strategies in first-line treatment of ES-SCLC

25P Differential response to platinum agents of patients carrying the germline BRCA1 c.211 A>G pathogenic variant

32P Validation of the Scottish Immunotherapy Prognostic Score (SIPS) in NSCLC patients treated with first-line pembrolizumab

P42.03 Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression

P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors

P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies

131P Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression

204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

Suchergebnisse filtern